Deep Brain Stimulation to the Subgenual Cingulate Gyrus for Treatment-Resistant Depression: A Randomized Controlled Trial and 2-Year Long-Term Follow-Up: Stimulation cérébrale profonde du gyrus cingulaire subgénual pour traiter la dépression résistante au traitement : Essai contrôlé à répartition aléatoire et suivi à long terme sur deux ans
The Canadian Journal of Psychiatry · 2026-04 · 71 (4) · 266-276
DOI: 10.1177/07067437251369226 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 31.10.2025. Verfasst von Peter Giacobbe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Depressive Disorder, Treatment-Resistant, Gyrus Cinguli, Major Depressive Disorder. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott Laboratories.
Themen: Depression
Abstract (Originalsprache)
Background
Trials of deep brain stimulation (DBS) to the subcallosal cingulate gyrus (SCG) for treatment-resistant depression (TRD) have yielded mixed results. While open-label studies suggest effectiveness, randomized controlled trials (RCTs) have not consistently supported these findings. The study compared the efficacy of active versus sham SCG stimulation for TRD.
Methods
Participants ( n = 35) in a major depressive episode and treatment resistance completed a 6-month double blind, crossover RCT, with an 18-month open-label phase. A Balaam design was applied with participants randomized to 1 of 4 stimulation groups over two 3-month phases. The primary outcome was a change in Hamilton Depression Rating Scale (HDRS) score at 6 months, with response defined as ≥50% reduction in HDRS-17 scores.
Results
While all groups showed improvement at 3 and 6 months, no significant differences were found among them. The OFF–OFF group had a numerically lower HDRS-17 score compared to the ON–ON group at the end of the RCT. No unexpected adverse events occurred. During the open-label phase, participants showed sustained reduction in HDRS-17 scores at 12, 18, and 24 months post-implantation, with successive observed-case response rates of 65.7%, 69%, and 73.1%, respectively. Improvements in life functioning were also noted.
Conclusions
This trial represents the largest single-centre, sham-controlled study of SCG DBS for TRD in the literature. Although the RCT showed no significant group differences, most participants achieved response during the open-label phase. Safety outcomes aligned with previous trials. Future RCTs should integrate insights from the past decade of DBS for TRD research to optimize outcomes. Key considerations include selecting DBS contact locations that ensure engagement of critical white matter tracts, employing novel and sufficiently long clinical trial designs to account for the non-specific effects of the DBS procedure, as well as incorporating biomarkers to guide DBS programming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Arthur Sommer Rotenberg Suicide & Depression Studies Program, St Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
- Centre for Depression and Suicide Studies, St Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Peter Giacobbe, Amanda K Ceniti, Gavin J B Elias, Jürgen Germann, Rima Styra, Andres M Lozano, Sidney H Kennedy
Förderung
- Abbott Laboratories
Zitieren
APA
Giacobbe, P., Rizvi, S. J., Ceniti, A. K., Tomlinson, G., Elias, G. J. B., Germann, J., Styra, R., Lozano, A. M., & Kennedy, S. H. (2026). Deep Brain Stimulation to the Subgenual Cingulate Gyrus for Treatment-Resistant Depression: A Randomized Controlled Trial and 2-Year Long-Term Follow-Up: Stimulation cérébrale profonde du gyrus cingulaire subgénual pour traiter la dépression résistante au traitement : Essai contrôlé à répartition aléatoire et suivi à long terme sur deux ans. The Canadian Journal of Psychiatry, 71(4), 266-276. https://doi.org/10.1177/07067437251369226
Vancouver
Giacobbe P, Rizvi SJ, Ceniti AK, Tomlinson G, Elias GJB, Germann J, et al. Deep Brain Stimulation to the Subgenual Cingulate Gyrus for Treatment-Resistant Depression: A Randomized Controlled Trial and 2-Year Long-Term Follow-Up: Stimulation cérébrale profonde du gyrus cingulaire subgénual pour traiter la dépression résistante au traitement : Essai contrôlé à répartition aléatoire et suivi à long terme sur deux ans. The Canadian Journal of Psychiatry. 2026;71(4):266-276. doi:10.1177/07067437251369226
BibTeX
@article{Giacobbe2026,
author = {Giacobbe, Peter and Rizvi, Sakina J and Ceniti, Amanda K and Tomlinson, George and Elias, Gavin J B and Germann, Jürgen and Styra, Rima and Lozano, Andres M and Kennedy, Sidney H},
title = {Deep Brain Stimulation to the Subgenual Cingulate Gyrus for Treatment-Resistant Depression: A Randomized Controlled Trial and 2-Year Long-Term Follow-Up: Stimulation cérébrale profonde du gyrus cingulaire subgénual pour traiter la dépression résistante au traitement : Essai contrôlé à répartition aléatoire et suivi à long terme sur deux ans},
journal = {The Canadian Journal of Psychiatry},
year = {2026},
volume = {71},
number = {4},
pages = {266--276},
doi = {10.1177/07067437251369226}
}
EUVIMED